About CureVac
Pioneering advancements in mRNA
Our track record says it all: approximately 950 issued patents worldwide in the messenger RNA (mRNA) field. More than 700 passionate employees advancing a shared mission. A strong IP portfolio, with candidates advancing through the clinic. Collaborations with some of the world’s preeminent leaders in the fight against cancer and other serious health conditions.
Now, it’s time to build upon our clinically validated technology and return to our strong R&D roots.
Our team is focused on expanding into new frontiers in both oncology and infectious disease. With our end-to-end manufacturing capabilities, we strive to close the gap in the small-scale production of oncology immunotherapies and accelerate the availability of life-changing treatments for patients. Because patients around the world simply can’t wait.
Leadership
Our team combines the distinct attributes needed to achieve success: an unwavering thirst for exploration and the deep expertise to deliver results. Our scientists working on mRNA therapies push the science of our uniquely positioned mRNA technology while our experts leading the clinical and regulatory aspects of our clinical development pipeline endeavor to bring medicines into the hands of people who need them.
Together, we are committed to charting a new and better future for those who live with a range of conditions with high unmet needs.
Executive board
Supervisory board
Collaborations
Beyond our world-class team, we forge collaborations with organizations that share in our mission to bring life-changing medicines from the lab to the clinic.
